The sustained delivery system of the antiinfection peptide LL37 — a potential new method of treatment of ocular infections. Report 3. Antimicrobial activity of LL37 encapsulated in silica nanoparticle

Authors

  • A. Buznyk State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)
  • N. Pasyechnikova State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)
  • S. Yakymenko State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)
  • A. Moloda State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)
  • M. M. Islam State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)
  • M. Griffith Linkoping University; Linkoping (Sweden)

DOI:

https://doi.org/10.31288/oftalmolzh2014548

Keywords:

eye infection, anti-infective peptide, system of constant drug delivery

Abstract

Purpose. To test anti-microbial activity of the anti-infection peptide (AIP) LL37 sustained delivery system (SDS) based on silica nanoparticles (SiNP).

Materials and Methods. AIP LL37 (cathelicidin) was encapsulated in SiNP under magnetic stirring. For anti-microbial activity testing, St. aureus and P. aeruginosa strains in the concentration 10' PFU/ml were co-cultured for 2 hours in nutrient broth together with LL37 SDS. Bacterium strains of the same concentrations cul­tured without LL37 SDS, with free LL37 or with empty SiNP served as controls. Culture medium was collected to count bacteria titer using plaque formation assay.

Results. SiNP encapsulated LL37had significant anti-microbial effect compared with controls: St. aureus titer in the culture medium contained SiNP encapsu­lated LL37was 3466.7+450.9PFU/ml, St. aureus titer in culture medium without SDS of LL37 was 410000+168226 PFU/ml (P = 0.012); P. aeruginosa titer in presence of SiNP encapsulated LL37 was 3.lxl07±l.85xl07 PFU/ml, its titer was 4.67xl0fl±2.08xl0n PFU/ml in the culture medium without SDS of LL37 (P =0.012).

Conclusion. For the first time there was shown in vitro the activity of anti-infective peptide system 0f constemt drug tive peptide LL37sustained delivery system based on silica nanoparticles against delivery gram-positive and gram-negative bacteria — St. aureus and P. aeruginosa.

References

1. Buznyk O. The sustained delivery system of the antiinfection peptide LL37 system - a potentially new treatment method of ocular infections. Report 1. Testing of different nano- and microparticles as carriers of LL37. Oftalmol Zh. 2014;2:17-21. Ukrainian. https://doi.org/10.31288/oftalmolzh201421721

2. Islam MM, Griffith M, Buznyk O. Anti-infective peptide LL37 sustained delivery system - a potential novel treat­ment method of ocular infections. Report 2. Anti-viral properties of silica nanoparticle encapsulated LL37. Oftal­mol Zh. 2014;3:53-7. Ukrainian. https://doi.org/10.31288/oftalmolzh201435357

3. Barlow PG, Svoboda P, Mackellar A et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS ONE. 2011;6(10): e25333. https://doi.org/10.1371/journal.pone.0025333

4. Balmayor ER, Azevedo HS, Reis RL. Controlled delivery systems: from pharmaceuticals to cells and genes. Pharm. Res. 2011;28:1241- 58. https://doi.org/10.1007/s11095-011-0392-y

5. Bertino JS Jr. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin. Ophthalmol. 2009;3:507- 21. https://doi.org/10.2147/OPTH.S5778

6. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature Rev. Microbiol.2005;3:238-50. https://doi.org/10.1038/nrmicro1098

7. Chetoni P, Rossi S, Burgalassi S et al. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits. J. Ocul. Pharmacol. Ther. 2004;20(2):169- 77.https://doi.org/10.1089/108076804773710849

8. Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D. Antibiotic discovery in the twenty-first century: Cur­rent trends and future perspectives. J. Antibiot. (Tokyo). 2010;63(8):423- 30.https://doi.org/10.1038/ja.2010.62

9. Fresta M, Fontana G, Bucolo C et al. Ocular tolerability and in vivo bioavailability of poly (ethyleneglycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulat-ed acyclovir. J. Pharm. Sci.2001;90(3):288- 97.https://doi.org/10.1002/1520-6017(200103)90:3<288::AID-JPS4>3.0.CO;2-5

10. Gordon YJ, Huang LC, Romanowski EG et al. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr. Eye Res. 2005;30(5):385- 94.https://doi.org/10.1080/02713680590934111

11. Griffith M, Polisetti N, Kuffova L et al. Regenerative approaches as alternatives to donor allografting for restora­tion of corneal function. Ocul. Surf. 2012;10 (3):170- 83.https://doi.org/10.1016/j.jtos.2012.04.004

12. Izquierdo-Barba I, Vallet-RegH M, Kupferschmidt N et al. Incorporation of antimicrobial compounds in mesoporous silica film monolith. Biomaterials. 2009;30(29):5729- 36.https://doi.org/10.1016/j.biomaterials.2009.07.003

13. Ramos R, Domingues L, Gama M. LL37, a human antimicrobial peptide with immunomodulatory properties. Science against microbial pathogens: communicating current research and technological advances : Microbiology Book Series [edit. A. Mnndez-Vilasj. Badajoz : Formatex Research Center. 2011; 2: 915-25.

14. Wang T, Huang X, Gao Q et al. A Preliminary Study to Treat Severe Endophthalmitis via a Foldable Capsular Vitreous Body with Sustained Levofloxacin Release in Rabbits. Invest. Ophthalmol. Vis. Sci. 2013;54:804- 12.https://doi.org/10.1167/iovs.12-9695

Downloads

Published

2014-10-30

Issue

No. 5 (2014): Journal of Ophthalmology (Ukraine)

Section

Clinical Ophthalmology

License

Copyright (c) 2014 О. І. Бузник, Н. В. Пасєчнікова, С. А. Якименко, А. Л. Молода, М. М. Іслам, М. Гріффіт

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.

COPYRIGHT NOTICE

Authors who publish in this journal agree to the following terms:

  1. Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
  2. The copyright commencement date complies the publication date of the issue, where the article is included in.

DEPOSIT POLICY

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
  3. Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
  4. Archiving the pre-print (pre-refereeing manuscript version) not allowed.

Most read articles by the same author(s)